E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients with first diagnosis of multiple myeloma and dialysis dependent acute renal failure secondary to cast nephropathy |
Patienten mit neu diagnostiziertem Multiplen Myelom und dialysepflichtigem Nierenersagen bei Cast Nephropathie |
|
E.1.1.1 | Medical condition in easily understood language |
Patients with first diagnosis of multiple myeloma and dialysis dependent acute renal failure secondary to cast nephropathy |
Patienten mit neu diagnostiziertem Multiplen Myelom und dialysepflichtigem Nierenersagen bei Cast Nephropathie |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Blood and lymphatic diseases [C15] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10028566 |
E.1.2 | Term | Myeloma |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10038436 |
E.1.2 | Term | Renal failure acute |
E.1.2 | System Organ Class | 100000004857 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10028569 |
E.1.2 | Term | Myelomatosis multiple |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10018875 |
E.1.2 | Term | Haemodialysis |
E.1.2 | System Organ Class | 10042613 - Surgical and medical procedures |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of the study is to address the hypothesis that, in combination with trial chemotherapy, extended haemodialysis (HD), using the high cut-off protein permeable Gambro HCO 1100 dialyser, increases the percentage of patients with cast nephropathy becoming independent of dialysis, as compared to conventional HD |
|
E.2.2 | Secondary objectives of the trial |
1) Investigation of the efficacy of extended HD using the Gambro HCO 1100 to result in sustained reductions in sFLC concentrations versus conventional HD. 2)It is proposed that patients with a cast nephropathy will recover their renal function more rapidly if their sFLC levels are reduced quickly. We will observe the duration of requirement for HD between the treatment and the control arms of the study. 3)The management of patients with MM is limited by renal impairment. It is conceivable that patients who recover renal function will have an increased chance of being suitable for high dose melphalan and stem cell transplantation, which is the current standard of care after primary chemotherapy. Response to treatment of MM will be documented at 6 and 12 months. Whether patients have received a stem cell transplant will be recorded at 12 months. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Age 18 years • Dialysis dependent acute renal failure (eGFR < 15 mls/min/1.73m²) • Fulfils criteria for the diagnosis of symptomatic de novo MM1 • Abnormal sFLC ratio and sFLC concentration > 500 mg/L • Myeloma kidney demonstrated on a renal biopsy (cast nephropathy) • Pre-menopausal female patients of childbearing potential: negative pregnancy test at enrolment and willingness to use effective contraception during the study and for 3 months after the end-of- study visit • Ability to understand objectives and risks of the trial and to comply with protocol requirements • Signed written informed consent • Commencement of study within 10 days of presenting to enrolling unit
|
|
E.4 | Principal exclusion criteria |
• Patients not meeting inclusion criteria • Known advanced chronic renal failure (CKD stage IV-V; eGFR < 30mls/min/ 1.73m2) or evidence of significant chronic damage on renal biopsy • Amyloidosis or light chain deposition disease on renal biopsy • Previous treatment of multiple myeloma with chemotherapy before this presentation with acute renal failure, except for dexamethasone • Haemodynamic instability that precludes unsupported renal replacement therapy • Significant cardiac disease (myocardial infarction with in the last 6 months; unstable angina; NYHA class III or IV heart failure; clinically significant pericardial disease; cardiac amyloidosis) • Advanced disease or significant co-morbidity: with poor short term prognosis, necessitating palliation and no active or disease specific treatment. • History of allergic reaction attributable to compounds containing boron or mannitol • Peripheral neuropathy or neuropathic pain (grade 2 or higher as defined by NCI CTCAE version 3) • Clinically significant liver dysfunction (bilirubin > 1.8mg/dl (30 µmol/L)) • Known HIV infection • Active uncontrolled infection • Participation in another investigational study within 90 days prior to enrolment • No contraception (men and pre-menopausal women) • Pregnancy and lactation • Any clinical condition or prior therapy that, in the opinion of the investigator, would make the patient unsuitable for the study
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary analysis for the trial is to compare the experimental treatment to the control treatment in terms of independence of dialysis at three months. The proportion of patients independent of dialysis will be compared using relative risks and chi-square tests. The analysis will be carried out on an intention-to-treat basis. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Independence of dialysis at three months after enrolment |
|
E.5.2 | Secondary end point(s) |
Efficacy of extended haemodialysis with respect to reduction of sFLC concentrations |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Daily measurement during bortezomib-treatment (max. 8 PAD cycles), afterwards single measurements at month 3, 6, 12 and 24 during follow up phase. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
conventional haemodialysis |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 7 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 11 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Regular termination of trial for each patient is completion of the last study visit at 24 months. The investigator will counsel the patient regarding continuation of follow-up outside the trial either in the regular outpatient clinic of the study site or by their local haematologist and or nephrologist. At regular termination of trial, patients have no trial related medication. The study is closed upon the last patient having completed the 24 month study visit. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |